UBS Group Lowers IQVIA (NYSE:IQV) Price Target to $255.00

IQVIA (NYSE:IQV) had its price target reduced by UBS Group from $260.00 to $255.00 in a report issued on Friday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other equities research analysts have also issued reports on IQV. Robert W. Baird dropped their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Truist Financial lowered their price target on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Redburn Atlantic started coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Finally, Leerink Partners restated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Price Performance

IQVIA stock opened at $208.13 on Friday. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The firm has a 50 day moving average price of $200.53 and a 200 day moving average price of $219.80. The company has a market cap of $37.78 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts predict that IQVIA will post 10.81 earnings per share for the current year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is owned by insiders.

Institutional Trading of IQVIA

Several institutional investors have recently modified their holdings of IQV. Smith Group Asset Management LLC acquired a new stake in IQVIA in the 4th quarter valued at about $1,616,000. Simplify Asset Management Inc. raised its holdings in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Fifth Third Bancorp grew its position in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.